查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2083753

法羅培南鈉市場：按劑型、包裝規格、治療應用、分銷管道和最終用戶分類的全球市場預測 – 2026–2032

Faropenem Sodium Market by Form, Pack Size, Therapeutic Application, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，法羅培南鈉市場規模將成長至 4.2787 億美元，複合年成長率為 7.45%。

主要市場統計數據
基準年 2025 2.586億美元
預計年份：2026年 2.771億美元
預測年份 2032 4.2787億美元
複合年成長率 (%) 7.45%

介紹

法羅培南鈉是一種口服的培南類BETA-內醯胺類抗生素，適用於臨床醫生需要對特定革蘭氏陽性菌、革蘭氏陰性菌和厭氧菌具有廣譜抗菌活性，同時又需要保留腸外碳青黴烯類抗生素用於嚴重感染疾病的場合。其重要性與持續存在的抗生素抗藥性問題、門診病人感染疾病管理以及支持合理抗生素治療的口服治療方案密切相關。

市場環境的變革性變化

法羅培南鈉的市場格局正受到三個因素的重塑：抗藥性監測、監管審查、以及實證用藥的需求。醫療系統正日益摒棄廣泛的經驗性用藥，轉而將抗生素的取得與適當的抗生素使用規則、藥敏試驗和當地治療指南相結合。

人工智慧的累積影響

人工智慧 (AI) 正成為法羅培南鈉整個價值鏈中累積加速發展的因素，尤其是在抗菌藥物抗藥性監測、處方分析和生產品管方面。 AI 驅動的監測可以揭示區域抗藥性模式與處方行為之間的相關性，從而支持更合理地使用口服BETA-內醯胺類抗生素。

關鍵區域洞察

由於日本和印度等國家對口服培南類藥物的認知度較高，亞太地區感染疾病門診病人數量龐大，擁有完善的國內製藥生產基地，且診斷能力不斷提升，因此該地區在戰略上對法羅培南鈉而言最為重要。北美地區由於尚未獲得美國食品藥物管理局（FDA）的批准，因此仍受到很大限制。因此，該地區的重要性在於監管基準研究、臨床研究以及抗菌藥物合理使用資訊收集，而非立即大規模商業化。

關鍵群體特定見解

東協市場具有成長潛力，這得益於醫療保健服務覆蓋範圍的擴大、私立醫院網路的不斷發展以及診斷技術的日益普及，所有這些因素都推動了對高效口服抗生素的需求。然而，各國抗菌藥物管理政策和法規的成熟度有差異。海灣合作理事會（GCC）成員國的特點是集中採購系統、健全的醫院管治以及完善的抗菌藥物抗藥性控制項目，因此，臨床證據、處方集納入標準和供應可靠性是推廣應用的關鍵因素。

主要國家的概況

美國主要作為監管嚴格程度的參考市場，因為法羅培南尚未獲得美國食品藥物管理局（FDA）的批准。加拿大也同樣強調實證核准和合理使用抗生素。墨西哥和巴西由於私人醫療保健的擴張、對感染疾病治療的需求以及法律規範體系的不斷發展，提供了有限的市場機會，但仍需在註冊、定價、醫生教育和品質定位等方面進行仔細考慮。在歐洲，英國、德國、法國、義大利和西班牙對抗生素的合理使用、報銷審查和處方控制都十分嚴格，而俄羅斯在監管、採購和供應鏈方面則有著其獨特的環境。

為行業領導者提供的實用建議

產業領導者應優先考慮負責任的市場開發，而非僅僅追求銷售量成長。最有效的策略是將法羅培南鈉的商業化與藥敏試驗數據、醫生教育、藥物安全監測系統以及抗菌藥物合理使用的要求相結合。

調查方法

本執行摘要採用系統的二手研究框架編寫，重點關注監管環境、合理使用抗菌藥物的趨勢、臨床應用背景、區域醫療保健趨勢以及藥品供應鏈中的相關因素。主要資訊來源包括公共監管資料庫、國家治療指南、同儕審查文獻、世界衛生組織（WHO）抗菌藥物抗藥性數據以及公共衛生機構資料。

結論

法羅培南鈉作為一種口服培南類藥物，在全球抗菌藥物市場中佔據有限但重要的地位，主要用於治療特定細菌感染疾病，並作為合理使用抗生素的處方藥物。在監管部門批准、醫生認知度高、診斷支持到位且供應穩定的地區，其市場潛力最大。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：法羅培南鈉市場：依劑型分類

  • 糖漿
  • 藥片

第8章：法羅培南鈉市場：依包裝規格分類

  • 瓶子
  • 小袋

第9章：法羅培南鈉市場：依治療應用分類

  • 婦科感染疾病
  • 呼吸道感染疾病
  • 皮膚和軟組織感染疾病
  • 尿道感染（UTI）

第10章：法羅培南鈉市場：依分銷管道分類

  • 物理藥房
    • 醫院藥房
    • 零售藥房
  • 網路藥房

第11章：法羅培南鈉市場：依最終用戶分類

  • 門診部
  • 醫院和診所

第12章：法羅培南鈉市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章：法羅培南鈉市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：法羅培南鈉市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Adooq Bioscience LLC
  • Alkem Laboratories Ltd.
  • Angle Bio Pharma
  • Arlak Biotech Pvt. Ltd.
  • Asterisk Healthcare
  • Canagen Pharmaceuticals Inc.
  • Casca Remedies Pvt. Ltd.
  • Cipla Limited
  • Conscientia Industrial Co., Ltd.
  • Fawn Incor Pvt. Ltd.
  • G-Biosciences
  • Glenmark Pharmaceuticals Limited
  • Honour Lab Limited
  • Hunan Warrant Chiral Pharmaceutical Co., Ltd.
  • Jabs Biotech PVT. LTD.
  • Lunan Pharmaceutical Group Ltd.
  • Maruho Co., Ltd.
  • Metrochem API Private Limited
  • Neuracle Lifesciences Private Limited
  • Shandong Chenlong Pharmaceutical Co., Ltd.
  • SimSon Pharma Limited
Product Code: MRR-4306E173CF24

The Faropenem Sodium Market is projected to grow by USD 427.87 million at a CAGR of 7.45% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 258.60 million
Estimated Year [2026] USD 277.10 million
Forecast Year [2032] USD 427.87 million
CAGR (%) 7.45%

Introduction

Faropenem sodium is an oral penem-class beta-lactam antibiotic positioned for treatment settings where clinicians need broad activity against selected Gram-positive, Gram-negative, and anaerobic organisms while preserving parenteral carbapenems for severe infections. Its relevance is tied to antimicrobial resistance, outpatient infection management, and the continued need for oral options that support appropriate antibiotic stewardship.

The commercial landscape remains specialized rather than universal. Faropenem has established clinical and market visibility in select Asian markets, while it is not broadly approved across major Western regulatory systems such as the United States. For SEO and market intelligence purposes, the most important keywords include Faropenem Sodium, oral penem antibiotic, beta-lactam antibiotics, antimicrobial resistance, bacterial infection treatment, and antibiotic stewardship.

Transformative Shifts in the Landscape

The Faropenem Sodium landscape is being reshaped by three forces: resistance surveillance, regulatory scrutiny, and the need for evidence-based prescribing. Health systems are increasingly aligning antibiotic access with stewardship rules, susceptibility testing, and local treatment guidelines rather than broad empirical expansion.

A second shift is the migration of value from simple product availability to differentiated clinical positioning. Suppliers, manufacturers, and commercial partners must now demonstrate reliable quality, pharmacovigilance readiness, and responsible marketing. In markets where faropenem is available, demand is most defensible when supported by microbiology data and clear use cases across respiratory, urinary, skin, soft tissue, dental, and other physician-directed bacterial infections.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a cumulative accelerator across the Faropenem Sodium value chain, especially in antimicrobial resistance monitoring, prescribing analytics, and manufacturing quality control. AI-enabled surveillance can help correlate local susceptibility patterns with prescribing behavior, supporting more precise use of oral beta-lactam antibiotics.

In research and development, machine learning can assist with beta-lactam structure-activity analysis, resistance mechanism mapping, and formulation optimization. In commercial operations, AI can improve demand forecasting, detect supply disruptions, and support pharmacovigilance signal triage. The strongest long-term impact will come from combining AI with laboratory-confirmed susceptibility data and clinically governed antibiotic stewardship programs.

Key Regional Insights

Asia-Pacific is the most strategically relevant region for Faropenem Sodium because of higher familiarity with oral penem therapy in countries such as Japan and India, combined with large outpatient infection volumes, domestic pharmaceutical manufacturing depth, and expanding diagnostic capacity. North America remains more constrained because faropenem is not approved by the U.S. Food and Drug Administration, making the region more relevant for regulatory benchmarking, clinical research, and antimicrobial stewardship intelligence than immediate broad commercialization.

Europe is shaped by rigorous antimicrobial stewardship, centralized quality expectations, pharmacovigilance discipline, and country-level reimbursement controls, while Latin America presents selective opportunities where regulatory pathways, private healthcare expansion, and physician education can support responsible access. The Middle East, particularly advanced Gulf health systems, is increasingly focused on formulary governance, centralized procurement, and infection-control standards, whereas Africa requires access strategies that balance affordability, quality assurance, antimicrobial resistance monitoring, and sustainable distribution across diverse healthcare systems.

Key Group Insights

ASEAN markets provide growth potential where expanding healthcare access, private hospital networks, and rising diagnostic adoption support demand for effective oral antibiotics, although stewardship policies and regulatory maturity vary by country. The GCC is characterized by centralized procurement, strong hospital governance, and growing antimicrobial resistance programs, making clinical evidence, formulary alignment, and supply reliability decisive for adoption.

The European Union emphasizes regulatory discipline, pharmacovigilance, and antimicrobial stewardship, while BRICS countries combine high infection burden with major generic manufacturing capability, large treatment volumes, and diverse regulatory maturity. G7 markets set the benchmark for clinical evidence, quality standards, reimbursement scrutiny, and responsible antibiotic commercialization. NATO-aligned countries are also strengthening medical supply resilience, which can elevate interest in diversified antibiotic sourcing without weakening stewardship controls or evidence-based prescribing requirements.

Key Country Insights

The United States is primarily a reference market for regulatory rigor because faropenem does not have FDA approval, while Canada similarly emphasizes evidence-based authorization and antimicrobial stewardship. Mexico and Brazil offer selective opportunities through expanding private healthcare, infectious disease treatment demand, and evolving regulatory oversight, but require careful registration, pricing, physician education, and quality positioning. In Europe, the United Kingdom, Germany, France, Italy, and Spain are governed by strict antibiotic stewardship, reimbursement scrutiny, and prescribing governance, while Russia presents a distinct regulatory, procurement, and supply-chain environment.

China and India are central to Asia-Pacific evaluation because they combine large patient populations, domestic pharmaceutical manufacturing, high outpatient antibiotic utilization, and heightened antimicrobial resistance concerns. Japan remains highly relevant due to established faropenem experience and disciplined prescribing frameworks. Australia and South Korea reflect advanced regulatory expectations, strong hospital stewardship, sophisticated diagnostics, and high pharmacovigilance standards, making them attractive for evidence-driven positioning rather than broad, promotion-led expansion.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize responsible market development over volume-only expansion. The strongest strategy is to align Faropenem Sodium commercialization with susceptibility data, physician education, pharmacovigilance systems, and antibiotic stewardship requirements.

Manufacturers should strengthen quality-by-design practices, diversify active pharmaceutical ingredient sourcing, and maintain transparent documentation for regulators and procurement bodies. Commercial teams should segment markets by regulatory feasibility, diagnostic maturity, guideline fit, reimbursement potential, and prescriber familiarity. Digital tools and AI should be used to improve antimicrobial resistance surveillance, demand planning, supply-chain continuity, and compliance rather than to encourage inappropriate antibiotic use.

Research Methodology

This executive summary is developed using a structured secondary-research framework that emphasizes regulatory status, antimicrobial stewardship trends, clinical-use context, regional healthcare dynamics, and pharmaceutical supply-chain factors. Priority sources typically include public regulatory databases, national treatment guidance, peer-reviewed literature, World Health Organization antimicrobial resistance resources, and public health agency materials.

The methodology applies cross-validation across clinical, regulatory, and commercial evidence to avoid unsupported claims. Market insights are interpreted through qualitative triangulation rather than speculative sizing, with particular attention to approved-use geographies, resistance patterns, procurement models, manufacturing quality expectations, pharmacovigilance requirements, and the evolving role of digital surveillance in antibiotic management.

Conclusion

Faropenem Sodium occupies a focused but important position in the global antibiotic landscape as an oral penem option relevant to selected bacterial infections and stewardship-aware prescribing. Its opportunity is strongest where regulatory authorization, physician familiarity, diagnostic support, and reliable supply converge.

Future progress will depend less on broad promotion and more on evidence-based positioning, resistance-informed use, and high-quality manufacturing. Organizations that combine clinical credibility, responsible access, regional precision, and AI-enabled surveillance will be better placed to compete in the Faropenem Sodium market while supporting global antimicrobial resistance objectives.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Faropenem Sodium Market, by Form

  • 7.1. Syrup
  • 7.2. Tablets

8. Faropenem Sodium Market, by Pack Size

  • 8.1. Bottles
  • 8.2. Sachets

9. Faropenem Sodium Market, by Therapeutic Application

  • 9.1. Gynecological Infections
  • 9.2. Respiratory Tract Infections
  • 9.3. Skin & Soft Tissue Infections
  • 9.4. Urinary Tract Infections (UTIs)

10. Faropenem Sodium Market, by Distribution Channel

  • 10.1. Offline Pharmacy
    • 10.1.1. Hospital Pharmacy
    • 10.1.2. Retail Pharmacy
  • 10.2. Online Pharmacy

11. Faropenem Sodium Market, by End User

  • 11.1. Ambulatory Care Centers
  • 11.2. Hospitals & Clinics

12. Faropenem Sodium Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Faropenem Sodium Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Faropenem Sodium Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Concentration Analysis, 2025
    • 15.1.1. Concentration Ratio (CR)
    • 15.1.2. Herfindahl Hirschman Index (HHI)
  • 15.2. Recent Developments & Impact Analysis, 2025
  • 15.3. Product Portfolio Analysis, 2025
  • 15.4. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Adooq Bioscience LLC
  • 16.2. Alkem Laboratories Ltd.
  • 16.3. Angle Bio Pharma
  • 16.4. Arlak Biotech Pvt. Ltd.
  • 16.5. Asterisk Healthcare
  • 16.6. Canagen Pharmaceuticals Inc.
  • 16.7. Casca Remedies Pvt. Ltd.
  • 16.8. Cipla Limited
  • 16.9. Conscientia Industrial Co., Ltd.
  • 16.10. Fawn Incor Pvt. Ltd.
  • 16.11. G-Biosciences
  • 16.12. Glenmark Pharmaceuticals Limited
  • 16.13. Honour Lab Limited
  • 16.14. Hunan Warrant Chiral Pharmaceutical Co., Ltd.
  • 16.15. Jabs Biotech PVT. LTD.
  • 16.16. Lunan Pharmaceutical Group Ltd.
  • 16.17. Maruho Co., Ltd.
  • 16.18. Metrochem API Private Limited
  • 16.19. Neuracle Lifesciences Private Limited
  • 16.20. Shandong Chenlong Pharmaceutical Co., Ltd.
  • 16.21. SimSon Pharma Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL FAROPENEM SODIUM MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL FAROPENEM SODIUM MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL FAROPENEM SODIUM MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL FAROPENEM SODIUM MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL FAROPENEM SODIUM MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL FAROPENEM SODIUM MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL FAROPENEM SODIUM MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL FAROPENEM SODIUM MARKET SIZE, BY FORM, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL FAROPENEM SODIUM MARKET SIZE, BY FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL FAROPENEM SODIUM MARKET SIZE, BY PACK SIZE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL FAROPENEM SODIUM MARKET SIZE, BY PACK SIZE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL FAROPENEM SODIUM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL FAROPENEM SODIUM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL FAROPENEM SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL FAROPENEM SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL FAROPENEM SODIUM MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL FAROPENEM SODIUM MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL FAROPENEM SODIUM MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL FAROPENEM SODIUM MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL FAROPENEM SODIUM MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL FAROPENEM SODIUM MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL FAROPENEM SODIUM MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL FAROPENEM SODIUM MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL FAROPENEM SODIUM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL FAROPENEM SODIUM MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL SYRUP MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL SYRUP MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL SYRUP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL TABLETS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL TABLETS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL FAROPENEM SODIUM MARKET SIZE, BY PACK SIZE, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BOTTLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BOTTLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BOTTLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL SACHETS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL SACHETS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL SACHETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL FAROPENEM SODIUM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GYNECOLOGICAL INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GYNECOLOGICAL INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GYNECOLOGICAL INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL RESPIRATORY TRACT INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL RESPIRATORY TRACT INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL RESPIRATORY TRACT INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL SKIN & SOFT TISSUE INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL SKIN & SOFT TISSUE INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SKIN & SOFT TISSUE INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL URINARY TRACT INFECTIONS (UTIS) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL URINARY TRACT INFECTIONS (UTIS) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL URINARY TRACT INFECTIONS (UTIS) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL FAROPENEM SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL OFFLINE PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL OFFLINE PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL OFFLINE PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL FAROPENEM SODIUM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL AMBULATORY CARE CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL AMBULATORY CARE CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL AMBULATORY CARE CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL FAROPENEM SODIUM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC FAROPENEM SODIUM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC FAROPENEM SODIUM MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC FAROPENEM SODIUM MARKET SIZE, BY PACK SIZE, 2018-2032 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC FAROPENEM SODIUM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC FAROPENEM SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC FAROPENEM SODIUM MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC FAROPENEM SODIUM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 57. NORTH AMERICA FAROPENEM SODIUM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA FAROPENEM SODIUM MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 59. NORTH AMERICA FAROPENEM SODIUM MARKET SIZE, BY PACK SIZE, 2018-2032 (USD MILLION)
  • TABLE 60. NORTH AMERICA FAROPENEM SODIUM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA FAROPENEM SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA FAROPENEM SODIUM MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA FAROPENEM SODIUM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 64. LATIN AMERICA FAROPENEM SODIUM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 65. LATIN AMERICA FAROPENEM SODIUM MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 66. LATIN AMERICA FAROPENEM SODIUM MARKET SIZE, BY PACK SIZE, 2018-2032 (USD MILLION)
  • TABLE 67. LATIN AMERICA FAROPENEM SODIUM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA FAROPENEM SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA FAROPENEM SODIUM MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA FAROPENEM SODIUM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE FAROPENEM SODIUM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE FAROPENEM SODIUM MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE FAROPENEM SODIUM MARKET SIZE, BY PACK SIZE, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE FAROPENEM SODIUM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE FAROPENEM SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE FAROPENEM SODIUM MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE FAROPENEM SODIUM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 78. MIDDLE EAST FAROPENEM SODIUM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 79. MIDDLE EAST FAROPENEM SODIUM MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 80. MIDDLE EAST FAROPENEM SODIUM MARKET SIZE, BY PACK SIZE, 2018-2032 (USD MILLION)
  • TABLE 81. MIDDLE EAST FAROPENEM SODIUM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 82. MIDDLE EAST FAROPENEM SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. MIDDLE EAST FAROPENEM SODIUM MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 84. MIDDLE EAST FAROPENEM SODIUM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. AFRICA FAROPENEM SODIUM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 86. AFRICA FAROPENEM SODIUM MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 87. AFRICA FAROPENEM SODIUM MARKET SIZE, BY PACK SIZE, 2018-2032 (USD MILLION)
  • TABLE 88. AFRICA FAROPENEM SODIUM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 89. AFRICA FAROPENEM SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 90. AFRICA FAROPENEM SODIUM MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 91. AFRICA FAROPENEM SODIUM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL FAROPENEM SODIUM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. ASEAN FAROPENEM SODIUM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 94. ASEAN FAROPENEM SODIUM MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 95. ASEAN FAROPENEM SODIUM MARKET SIZE, BY PACK SIZE, 2018-2032 (USD MILLION)
  • TABLE 96. ASEAN FAROPENEM SODIUM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 97. ASEAN FAROPENEM SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. ASEAN FAROPENEM SODIUM MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 99. ASEAN FAROPENEM SODIUM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. GCC FAROPENEM SODIUM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 101. GCC FAROPENEM SODIUM MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 102. GCC FAROPENEM SODIUM MARKET SIZE, BY PACK SIZE, 2018-2032 (USD MILLION)
  • TABLE 103. GCC FAROPENEM SODIUM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 104. GCC FAROPENEM SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 105. GCC FAROPENEM SODIUM MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 106. GCC FAROPENEM SODIUM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPEAN UNION FAROPENEM SODIUM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPEAN UNION FAROPENEM SODIUM MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPEAN UNION FAROPENEM SODIUM MARKET SIZE, BY PACK SIZE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPEAN UNION FAROPENEM SODIUM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPEAN UNION FAROPENEM SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPEAN UNION FAROPENEM SODIUM MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPEAN UNION FAROPENEM SODIUM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. BRICS FAROPENEM SODIUM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 115. BRICS FAROPENEM SODIUM MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 116. BRICS FAROPENEM SODIUM MARKET SIZE, BY PACK SIZE, 2018-2032 (USD MILLION)
  • TABLE 117. BRICS FAROPENEM SODIUM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 118. BRICS FAROPENEM SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. BRICS FAROPENEM SODIUM MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 120. BRICS FAROPENEM SODIUM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. G7 FAROPENEM SODIUM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 122. G7 FAROPENEM SODIUM MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 123. G7 FAROPENEM SODIUM MARKET SIZE, BY PACK SIZE, 2018-2032 (USD MILLION)
  • TABLE 124. G7 FAROPENEM SODIUM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 125. G7 FAROPENEM SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. G7 FAROPENEM SODIUM MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 127. G7 FAROPENEM SODIUM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. NATO FAROPENEM SODIUM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 129. NATO FAROPENEM SODIUM MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 130. NATO FAROPENEM SODIUM MARKET SIZE, BY PACK SIZE, 2018-2032 (USD MILLION)
  • TABLE 131. NATO FAROPENEM SODIUM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 132. NATO FAROPENEM SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. NATO FAROPENEM SODIUM MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 134. NATO FAROPENEM SODIUM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL FAROPENEM SODIUM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. UNITED STATES FAROPENEM SODIUM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 137. UNITED STATES FAROPENEM SODIUM MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 138. UNITED STATES FAROPENEM SODIUM MARKET SIZE, BY PACK SIZE, 2018-2032 (USD MILLION)
  • TABLE 139. UNITED STATES FAROPENEM SODIUM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 140. UNITED STATES FAROPENEM SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. UNITED STATES FAROPENEM SODIUM MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 142. UNITED STATES FAROPENEM SODIUM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. CANADA FAROPENEM SODIUM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 144. CANADA FAROPENEM SODIUM MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 145. CANADA FAROPENEM SODIUM MARKET SIZE, BY PACK SIZE, 2018-2032 (USD MILLION)
  • TABLE 146. CANADA FAROPENEM SODIUM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 147. CANADA FAROPENEM SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. CANADA FAROPENEM SODIUM MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 149. CANADA FAROPENEM SODIUM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. MEXICO FAROPENEM SODIUM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 151. MEXICO FAROPENEM SODIUM MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 152. MEXICO FAROPENEM SODIUM MARKET SIZE, BY PACK SIZE, 2018-2032 (USD MILLION)
  • TABLE 153. MEXICO FAROPENEM SODIUM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 154. MEXICO FAROPENEM SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. MEXICO FAROPENEM SODIUM MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 156. MEXICO FAROPENEM SODIUM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. BRAZIL FAROPENEM SODIUM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 158. BRAZIL FAROPENEM SODIUM MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 159. BRAZIL FAROPENEM SODIUM MARKET SIZE, BY PACK SIZE, 2018-2032 (USD MILLION)
  • TABLE 160. BRAZIL FAROPENEM SODIUM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 161. BRAZIL FAROPENEM SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 162. BRAZIL FAROPENEM SODIUM MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 163. BRAZIL FAROPENEM SODIUM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. UNITED KINGDOM FAROPENEM SODIUM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 165. UNITED KINGDOM FAROPENEM SODIUM MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 166. UNITED KINGDOM FAROPENEM SODIUM MARKET SIZE, BY PACK SIZE, 2018-2032 (USD MILLION)
  • TABLE 167. UNITED KINGDOM FAROPENEM SODIUM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 168. UNITED KINGDOM FAROPENEM SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 169. UNITED KINGDOM FAROPENEM SODIUM MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 170. UNITED KINGDOM FAROPENEM SODIUM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. GERMANY FAROPENEM SODIUM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 172. GERMANY FAROPENEM SODIUM MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 173. GERMANY FAROPENEM SODIUM MARKET SIZE, BY PACK SIZE, 2018-2032 (USD MILLION)
  • TABLE 174. GERMANY FAROPENEM SODIUM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 175. GERMANY FAROPENEM SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 176. GERMANY FAROPENEM SODIUM MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 177. GERMANY FAROPENEM SODIUM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. FRANCE FAROPENEM SODIUM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 179. FRANCE FAROPENEM SODIUM MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 180. FRANCE FAROPENEM SODIUM MARKET SIZE, BY PACK SIZE, 2018-2032 (USD MILLION)
  • TABLE 181. FRANCE FAROPENEM SODIUM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 182. FRANCE FAROPENEM SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 183. FRANCE FAROPENEM SODIUM MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 184. FRANCE FAROPENEM SODIUM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. RUSSIA FAROPENEM SODIUM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 186. RUSSIA FAROPENEM SODIUM MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 187. RUSSIA FAROPENEM SODIUM MARKET SIZE, BY PACK SIZE, 2018-2032 (USD MILLION)
  • TABLE 188. RUSSIA FAROPENEM SODIUM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 189. RUSSIA FAROPENEM SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 190. RUSSIA FAROPENEM SODIUM MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 191. RUSSIA FAROPENEM SODIUM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. ITALY FAROPENEM SODIUM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 193. ITALY FAROPENEM SODIUM MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 194. ITALY FAROPENEM SODIUM MARKET SIZE, BY PACK SIZE, 2018-2032 (USD MILLION)
  • TABLE 195. ITALY FAROPENEM SODIUM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 196. ITALY FAROPENEM SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 197. ITALY FAROPENEM SODIUM MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 198. ITALY FAROPENEM SODIUM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. SPAIN FAROPENEM SODIUM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 200. SPAIN FAROPENEM SODIUM MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 201. SPAIN FAROPENEM SODIUM MARKET SIZE, BY PACK SIZE, 2018-2032 (USD MILLION)
  • TABLE 202. SPAIN FAROPENEM SODIUM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 203. SPAIN FAROPENEM SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 204. SPAIN FAROPENEM SODIUM MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 205. SPAIN FAROPENEM SODIUM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. CHINA FAROPENEM SODIUM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 207. CHINA FAROPENEM SODIUM MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 208. CHINA FAROPENEM SODIUM MARKET SIZE, BY PACK SIZE, 2018-2032 (USD MILLION)
  • TABLE 209. CHINA FAROPENEM SODIUM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 210. CHINA FAROPENEM SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA FAROPENEM SODIUM MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA FAROPENEM SODIUM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. INDIA FAROPENEM SODIUM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 214. INDIA FAROPENEM SODIUM MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 215. INDIA FAROPENEM SODIUM MARKET SIZE, BY PACK SIZE, 2018-2032 (USD MILLION)
  • TABLE 216. INDIA FAROPENEM SODIUM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 217. INDIA FAROPENEM SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 218. INDIA FAROPENEM SODIUM MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 219. INDIA FAROPENEM SODIUM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 220. JAPAN FAROPENEM SODIUM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 221. JAPAN FAROPENEM SODIUM MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 222. JAPAN FAROPENEM SODIUM MARKET SIZE, BY PACK SIZE, 2018-2032 (USD MILLION)
  • TABLE 223. JAPAN FAROPENEM SODIUM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 224. JAPAN FAROPENEM SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 225. JAPAN FAROPENEM SODIUM MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 226. JAPAN FAROPENEM SODIUM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. AUSTRALIA FAROPENEM SODIUM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 228. AUSTRALIA FAROPENEM SODIUM MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 229. AUSTRALIA FAROPENEM SODIUM MARKET SIZE, BY PACK SIZE, 2018-2032 (USD MILLION)
  • TABLE 230. AUSTRALIA FAROPENEM SODIUM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 231. AUSTRALIA FAROPENEM SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 232. AUSTRALIA FAROPENEM SODIUM MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 233. AUSTRALIA FAROPENEM SODIUM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 234. SOUTH KOREA FAROPENEM SODIUM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 235. SOUTH KOREA FAROPENEM SODIUM MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 236. SOUTH KOREA FAROPENEM SODIUM MARKET SIZE, BY PACK SIZE, 2018-2032 (USD MILLION)
  • TABLE 237. SOUTH KOREA FAROPENEM SODIUM MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 238. SOUTH KOREA FAROPENEM SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 239. SOUTH KOREA FAROPENEM SODIUM MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 240. SOUTH KOREA FAROPENEM SODIUM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)